HCPCS G9204: Hepatitis C RNA Testing Not Documented Within 12 Months

HCPCS Level II code G9204 is used to indicate that RNA testing for hepatitis C was not documented as performed within 12 months prior to initiation of antiviral treatment for hepatitis C, with no reason provided. Nationally, this code highlights gaps in documentation and potential lapses in pre-treatment diagnostic evaluation for hepatitis C, which can affect treatment planning and quality measurement.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code’s clinical significance, common sites of service where the code may appear, and the policy and documentation implications relevant to major payers. The publication summarizes benchmarks for documentation rates where available, recent policy updates affecting pre-treatment testing requirements, and the clinical context for hepatitis C RNA testing prior to antiviral initiation.

The report provides practical reference information for billing, coding, and quality teams seeking to understand how G9204 is used in claims and quality reporting, and what gaps it signals in care documentation. Data not available in the input is noted where applicable.

Billing Code Overview

HCPCS Level II code G9204 indicates that RNA testing for hepatitis C was not documented as performed within 12 months prior to initiation of antiviral treatment for hepatitis C, reason not given. This code documents a lack of documented RNA testing in the year before starting hepatitis C antiviral therapy.

Service type: Diagnostic laboratory testing documentation gap related to hepatitis C RNA testing
Typical site of service: Outpatient clinic or ambulatory care settings where hepatitis C antiviral treatment is initiated, including infectious disease, hepatology, and primary care clinics

Data not available in the input.

Clinical Context

A 56-year-old patient with chronic hepatitis C virus (HCV) infection presents to a hepatology clinic for initiation of direct-acting antiviral (DAA) therapy. Pre-treatment evaluation requires documentation of HCV RNA testing to confirm active viremia and to establish a baseline viral load prior to starting antiviral medication. During chart review, the clinician orders or confirms a quantitative HCV RNA PCR test; however, the medical record lacks documentation that an HCV RNA test was performed within the 12 months preceding the planned antiviral start date and no reason for the missing test is recorded. Typical clinical workflow includes intake history, review of prior lab results, ordering or repeating HCV RNA testing, counseling about therapy, medication reconciliation, and scheduling follow-up to review RNA results and confirm treatment initiation once active viremia is verified.

Coding Specifications

Modifier	Description	When to Use
`25`	Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure or other service	Use when an E/M visit is distinct from services related to HCV testing or treatment planning on the same date
`26`	Professional component

Taxonomy Code	Specialty	Notes
`207RG0100X`	Gastroenterology	Hepatologists and gastroenterologists commonly manage HCV treatment and order HCV RNA testing
`207RC0000X`	Infectious Disease	Infectious disease specialists evaluate and treat chronic HCV and interpret virologic testing
`208000000X`	Internal Medicine	Primary care internists often diagnose HCV and coordinate pre-treatment labs
`208D00000X`	Family Medicine	Family physicians may initiate HCV screening and referral for treatment
`363LF0000X`	Clinical Laboratory Director	Laboratory medical directors oversee testing platforms and result validation

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`B18.2`	Chronic viral hepatitis C	Primary diagnosis indicating chronic HCV infection and the main indication for HCV RNA testing prior to antiviral therapy
`K74.60`	Unspecified cirrhosis of liver	Cirrhosis staging influences urgency of HCV treatment and monitoring and supports baseline RNA testing
`K70.30`	Alcoholic cirrhosis of liver without ascites	Alcohol-related liver disease may coexist with HCV and affects treatment planning and monitoring
`E11.9`	Type 2 diabetes mellitus without complications	Common comorbidity that may impact liver disease progression and treatment considerations
`Z79.899`	Other long term (current) drug therapy	May be used when documenting chronic medication use during pre-treatment evaluation

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`87491`	Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C virus, amplified probe technique, qualitative	Often used to detect HCV RNA qualitatively when confirming active infection prior to treatment
`87522`	Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C virus, real-time reverse transcription, quantitative	Commonly used to measure HCV viral load quantitatively for baseline and on-treatment monitoring
`0004U`	Hepatitis C virus genotype and subtype by sequencing, next-generation sequencing	Performed prior to or during treatment selection to identify genotype or resistance-associated substitutions when relevant
`80053`	Comprehensive metabolic panel	Baseline chemistry panel frequently ordered alongside HCV RNA testing to assess liver and renal function before therapy
`82728`	Bilirubin; total	Component of liver function testing relevant to baseline assessment prior to antiviral therapy

OpenPayer

Summary & Overview